# Study of ZG0895.HCl in Patients With Advanced Solid Tumors

> **NCT05877664** · PHASE1 · RECRUITING · sponsor: **Suzhou Zelgen Biopharmaceuticals Co.,Ltd** · enrollment: 60 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** ZG0895 Hydrochloride for Injection

## Key facts

- **NCT ID:** NCT05877664
- **Lead sponsor:** Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-08
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05877664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05877664, "Study of ZG0895.HCl in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05877664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*